Research programme: anti-cancer therapeutics - Inflection Biosciences

Drug Profile

Research programme: anti-cancer therapeutics - Inflection Biosciences

Alternative Names: IBL-100 series; IBL-202; IBL-300 series; IBL-301; IBL-302

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spanish National Cancer Research Centre
  • Developer Inflection Biosciences; Multiple Myeloma Research Foundation; Trinity College Dublin; University of Sydney
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia; Haematological malignancies; Multiple myeloma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 17 Jul 2018 Preclinical trials in Chronic lymphocytic leukaemia in Ireland (unspecified route)
  • 17 Jul 2018 Pharmacodynamics data from a preclinical study in Chronic lymphocytic leukaemia released by Inflection Biosciences
  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top